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Abstract
Background:  Systemic  inﬂammation  is  characterised  by  high  circulating  levels  of  inﬂammatory
cytokines  and  increased  macrophage  inﬁltration  in  peripheral  tissues.  Most  importantly,  this
inﬂammatory  state  does  not  involve  damage  or  loss  of  function  of  the  inﬁltrated  tissue,  which
is a  distinctive  feature  of  the  low-grade  systemic  inﬂammation.  The  term  ‘‘meta-inﬂammation’’
has also  been  used  to  refer  to  the  low-grade  systemic  inﬂammation  due  to  its  strong  relationship
with the  development  of  cardio-metabolic  diseases  in  obesity.
Objective:  A  review  is  presented  on  the  recent  clinical  and  experimental  evidence  concerning
the role  of  adipose  tissue  inﬂammation  as  a  key  mediator  of  low-grade  systemic  inﬂammation.
Furthermore,  the  main  molecular  mechanisms  involved  in  the  inﬂammatory  polarisation  of
macrophages  with  the  ability  to  inﬁltrate  both  the  adipose  tissue  and  the  vascular  endothelium
via activation  of  toll-like  receptors  by  metabolic  damage-associated  molecular  patterns,  such
as advanced  glycation-end  products  and  oxidised  lipoproteins,  is  discussed.  Finally,  a  review
is made  of  the  pathogenic  mechanisms  through  which  the  low-grade  systemic  inﬂammation
contributes  to  develop  insulin  resistance,  dyslipidaemia,  atherogenesis,  type  2  diabetes,  and
hypertension  in  obese  individuals.
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Conclusions:  A  better  understanding  of  the  molecular  mechanisms  of  low-grade  systemic  inﬂam-
mation in  promoting  cardio-metabolic  diseases  is  necessary,  in  order  to  further  design  novel
anti-inﬂammatory  therapies  that  take  into  consideration  clinical  data,  as  well  as  the  circulat-
ing levels  of  cytokines,  immune  cells,  and  metabolic  damage-associated  molecular  patterns  in
each patient.
©  2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Inﬂamación  sistémica  de  grado  bajo  y  su  relación  con  el  desarrollo  de  enfermedades
metabólicas:  de  la  evidencia  molecular  a  la  aplicación  clínica
Resumen
Antecedentes:  La  inﬂamación  sistémica  se  caracteriza  por  la  elevación  en  los  niveles  circu-
lantes de  citocinas  inﬂamatorias;  así  como  aumento  en  la  inﬁltración  de  macrófagos  en  tejidos
periféricos.  Este  escenario  inﬂamatorio  no  induce  lesión  o  pérdida  de  la  funcionalidad  en  el
tejido inﬁltrado,  rasgo  distintivo  de  un  estado  de  inﬂamación  sistémica  de  grado  bajo.  La  inﬂa-
mación sistémica  de  grado  bajo  posee  una  estrecha  relación  con  el  desarrollo  de  enfermedades
cardiometabólicas  en  el  paciente  con  obesidad,  por  lo  que  este  estado  de  alteración  inmune
también  ha  recibido  el  nombre  de  metainﬂamación.
Objetivo:  En  esta  revisión  presentamos  la  evidencia  clínica  y  experimental  más  reciente  en
torno al  papel  de  la  inﬂamación  del  tejido  adiposo  como  detonante  de  la  metainﬂamación.
Además, revisamos  a  nivel  molecular  los  mecanismos  de  polarización  inﬂamatoria  de  macrófa-
gos invasores  del  tejido  adiposo  y  el  endotelio  vascular  a  través  de  la  activación  de  receptores
tipo toll  por  patrones  moleculares  asociados  a  dan˜o  metabólico,  tales  como  proteínas  glucosi-
ladas y  lipoproteínas  oxidadas.  Por  último,  revisamos  los  mecanismos  ﬁsiopatogénicos  de  la
inﬂamación  sistémica  en  el  desarrollo  de  resistencia  a  la  insulina,  dislipidemia,  aterogénesis,
diabetes mellitus  tipo  2  e  hipertensión  en  el  paciente  obeso.
Conclusiones:  Un  entendimiento  más  detallado  de  los  mecanismos  moleculares  a  través  de
los cuales  la  inﬂamación  sistémica  de  grado  bajo  promueve  el  desarrollo  de  enfermedades
cardiometabólicas  podría  ser  útil  en  el  disen˜o  de  terapias  antiinﬂamatorias  que  tengan  en
cuenta datos  clínicos,  así  como  el  nivel  circulante  de  citocinas,  células  inmunes  y  patrones
moleculares  asociados  a  dan˜o  metabólico  en  el  paciente.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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ecent  experimental  and  clinical  evidence  suggests  that
etabolic  syndrome  and  cardiovascular  disease  could  be
he  consequence  of  a  systemic  inﬂammatory  process.1
ystemic  inﬂammation  has  major  differences  to  a  classic
nﬂammatory  response  (Table  1).  Speciﬁcally,  systemic
nﬂammation  is  characterised  by  high  circulating  levels  of
cute-phase  proteins  and  active  inﬂammatory  cytokines,
ncluding  C-reactive  proteins  (pCr),  tumour  necrosis  factor
lfa  (TNF-) and  interleukins  (IL)  1,  6  and  17,  in  addition
o  an  increase  in  immune  cell  inﬁltration  including  that
f  macrophages  and  t  lymphocytes  in  insulin-dependent
issue.2,3 Furthermore,  there  is  a  consensus  of  opinion
hat  systemic  inﬂammation  does  not  cause  damage  in
mmunologically  inﬁltrated  tissue;  this  distinctive  trait  has
ed  to  the  term  low-grade  systemic  inﬂammation.3,4 In  other
ords,  during  a  state  of  low-grade  systemic  inﬂammation
issues  express  high  levels  of  inﬂammatory  factors  and
g
p
tmmune  cell  inﬁltration  whilst  simultaneously  not  express-
ng  any  structural  changes  or  loss  of  primary  functions.  By
ontrast,  due  to  its  close  relationship  with  the  development
f  cardio-metabolic  diseases  in  obese  patients,  low-grade
ystemic  inﬂammation  has  recently  been  referred  to  as
eta-inﬂammation  or  metabolic  inﬂammation.5
However,  despite  the  fact  that  the  relationship  between
ow-grade  systemic  inﬂammation  and  cardio-metabolic  dis-
ases  has  considerably  increased  during  the  last  decade,
any  elements  are  yet  to  be  researched  and  discussed  in  this
egard.  For  example,  which  cellular  mechanisms  drive  the
tart  and  perpetuation  of  meta-inﬂammation?  Which  molec-
lar  events  are  involved  in  the  clinical  outset  of  systemic
nﬂammation?  Is  there  any  existing  evidence  to  suggest  that
ow-grade  systemic  inﬂammation  is  the  backdrop  to  patholo-
ies  such  as  insulin  resistance,  dyslipidaemia,  high  blood
ressure  and  diabetes  mellitus  type  2?
Our  approach  in  this  review  is  to  tackle  each  of
he  before-mentioned  points,  exposing  the  most  recent
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Table  1  Main  differences  between  classical  and  low-grade  inﬂammation.
Classical  inﬂammation  Low-grade  systemic  inﬂammation
Duration  Acute,  subacute Chronic
Location  Local  Systemic,  insulin  dependent  tissue
Cell inﬁltration  Neutrophils,  eosinophils,  NK  cells,  T
lymphocytes,  macrophages
Macrophages,  T  lymphocytes
Cytokines and  soluble  factors  TNF-,  IL-1, IL-6,  ROS  TNF-,  IL-6,  reactive  protein  C,  ROS
Activators PAMP  and  DAMP  Metabolic  DAMP
Tissue injury  Present  Absent
Associated  pathologies  Colitis,  peritonitis,  SIRS,  etc.  Dyslipidaemia,  atherogenesis,
diabetes  mellitus  type  2,  systemic
arterial  hypertension
DAMP: damage associated molecular patterns; ROS: reactive oxygen species; NK: natural killer cells; IL: interleukin; PAMP: pathogen-
associated molecular patterns; SIRS: systemic inﬂammatory response syndrome; TNF: tumour necrosis factor.
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winformation  with  regards  to  low-grade  systemic  inﬂamma-
tion  and  its  relationship  with  the  development  of  cardio-
metabolic  changes  from  a  molecular  and  clinical  viewpoint.
Particular  emphasis  will  be  placed  on  the  application  of  this
knowledge  to  the  identiﬁcation  of  possible  biomarkers  and
therapeutic  targets  which  may  lead  to  improvements  in  the
treatment  of  patients  with  metabolic  changes.
Inﬂammation  of  visceral  adipose  tissue:  the
beginning of  low-grade  systemic  inﬂammation
One  of  the  ﬁrst  mechanisms  involved  at  the  start  of  low-
grade  systemic  inﬂammation  is  the  inﬂammation  of  white
or  visceral  adipose  tissue  (Fig.  1)  As  a  consequence  of  the
imbalance  between  energy  intake  and  outputs,  adipocytes
tend  to  accumulate  large  amounts  of  fatty  acids  inside
them,  which  leads  to  the  white  adipose  tissue  expanding  in
processes  such  as  adipocitary  hyperplasia  and  hypertrophy
(increase  in  number  and  size,  respectively).  In  response  to
modiﬁcations  in  the  domain  of  the  stromal  vascular  frac-
tioning  of  the  visceral  adipose  tissue,  several  adipocytes
located  in  areas  at  some  distance  from  blood  vessels  suf-
fer  from  hypoxia  and  later  from  necrosis,  after  which
they  are  surrounded  by  phagocytic  cells  which  initiate  an
inﬂammatory  state  aimed  at  removing  these  cells.6 The
large  amount  of  fatty  acids  stored  in  these  cells  may
exacerbate  oxidative  processes  such  as  lipid  peroxidation,
consisting  of  the  oxidation  of  lipid  molecules  inside  the
adipocyte.  Lipid  peroxidation  which  develops  during  adipoc-
itary  hyperplasia/hypertrophy  induces  a  scenario  of  cellular
oxidative  stress  characterised  by  a  considerable  rise  in
reactive  species  levels  of  oxygen  and  nitrogen,  including
superoxide  ions  (O2−)  and  nitric  oxide  (ON)  respectively.
A  consequence  of  this  oxidative  explosion  the  recruitment
of  numerous  immunological  cells  from  the  periphery  to  the
adipose  tissue,  initiating  a  local  level  inﬂammatory  process
characterised  by  a  rise  in  TNF- and  leptin  levels,  and  a
reduction  in  IL-10  and  adiponectin.6 However,  under  stress-
ful  conditions  such  as  hypoxia  and  hyperoxidation  of  fatty
acids,  functional  changes  occur  in  the  adipocytes  charac-
terised  by  marked  reticular  stress  associated  with  incorrect
protein  folding  processes  and  autophagy,  with  possible  onset
o
i
l
bf  apoptosis  in  these  cells.7 In  addition  to  the  cellular  events
escribed  above,  this  apoptotoic  process  converges  at  an
ssential  point  in  the  initiation  of  the  low-grade  systemic
nﬂammation,  the  inﬂammation  of  white  adipose  tissue.
Histologically,  the  inﬂammation  of  adipose  tissue  is  char-
cterised  by  an  inﬁltration  mainly  composed  of  macrophages
nd  secondarily  cytotoxic  T  lymphocytes,  with  the  absence
f  or  very  little  presence  of  neutrophils.3,8 The  macrophages
re  surrounded  by  adipocytes  forming  a  crown-like  struc-
ure  (CLS);  a  distinctive  feature  of  low-grade  inﬂammation
n  adipose  tissue.6 It  is  important  to  underline  that
he  inﬁltration  of  immune  cells  is,  per  se,  a  perma-
ent  source  of  cytokines  and  pro-inﬂammatory  factors  in
yperplasic  and  hypertrophic  adipose  tissue  exhibiting  high
evels  of  IL-1, IL-6,  TNF- and  leptin,  in  addition  to  a
reater  production  of  proteins  with  chemo-attractive  or
hemokine  proteins.9 Hyperplasic  and  hypertrophic  adi-
ose  tissue  express  high  concentrations  of  chemokines  such
s  the  macrophage  chemo-attractive  protein  (MCP-1),  the
acrophage  inhibitory  factor  (MIF-1)  and  RANTES,  all  of
hich  are  able  to  attract  more  macrophages  and  peripheral
ymphocytes,  thus  perpetuating  the  tissue  immune  inva-
ion  process.  Moreover,  there  is  a  growing  body  of  evidence
o  suggest  that  changes  on  hyperplasic  and  hypertrophic
isceral  adipose  tissue  level  changes  may  not  only  have
utocrine  and  paracrine  but  also  endocrine  involvement,
ue  to  the  fact  that  in  patients  with  different  obesity
evels  signiﬁcantly  higher  elevated  circulating  levels  of
nﬂammatory  cytokines,  chemokines  and  macrophages  and
onocytes  have  been  observed.1,2,10
During  obesity  inﬂammation  of  the  visceral  adipose  tis-
ue  may  therefore  trigger  a  systemic  inﬂammation  process,
hich  affects  other  insulin-dependent  tissues  such  as  those
f  the  liver  and  muscles,  thus  perpetuating  the  inﬂamma-
ory  state  on  an  adipocytary  level.  Up  until  now,  we  have
escribed  the  cellular  environment  underlying  visceral  adi-
ose  tissue  inﬂammation  and  its  possible  contribution  to
he  development  of  low-grade  systemic  inﬂammation.  But
hich  molecular  mechanisms  are  involved  in  the  polarisation
f  the  macrophage  towards  the  inﬂammatory  proﬁle  with
ts  consequent  release  of  TNF- and  the  establishment  of
ow-grade  systemic  inﬂammation?  We  will  address  this  issue
elow.
546  J.I.  León-Pedroza  et  al.
Inflammatory effect
is lowered
Raises insulin
sensitivity 
Adiponectin
Promotes the
inflammatory effect
decreases insulin
sensitivity
Leptin
Obesity
Hypertrophy of adipose
tissue ↑ Infiltrated pro-inflammatory
macrophages 
Raises insulin
resistanceLGSIFFA
OxLDL
AGE ↑ Apoptosis by caspasa-1
↑ Adipocitary inflammation
Adipose tissue
↑ IL-1β, IL6, IL18, TNF- α
↓ IL-10
Figure  1  Inﬂammation  of  visceral  adipose  tissue  is  a  trigger  signalling  the  beginning  and  the  spread  of  low-grade  systemic  inﬂam-
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xidised low  density  lipo  proteins;  TNF:  tumour  necrosis  factor.
he  beginning  of  low-grade  systemic  inﬂammation
epends on  the  activation  of  pattern  recognition
eceptors
mmune  cells,  such  as  macrophages  and  dendritic  cells
xpress  a  group  of  membrane  receptors  which  form  part
f  the  innate  response  to  external  and  internal  stimulae
nown  as  pattern  recognition  receptors  (PRRs).  In  gen-
ral,  PRRs  are  able  to  detect  two  types  of  molecules,
he  pathogen-associated  molecular  patterns  (PAMP)  and  the
amage-associated  molecular  patterns  (DAMP).  PAMP  are
olecules  derived  from  pathogen  microorganisms  whilst
AMP  are  released  by  tissues  which  have  suffered  some
ype  of  damage.  The  interaction  between  PRRs  with  PAMP
r  DAMP  leads  to  rapid  response  to  infection  or  damage  to
issue  respectively,  through  the  activation  of  the  inﬂamma-
ory  response  and/or  tissue  repair.  It  is  important  to  mention
hat  the  term  PAMP  is  currently  subject  to  debate  since
on-pathogen  microorganisms  also  possess  many  of  these
olecular  structures  and  are  capable  of  inducing  an  immune
esponse,  such  as,  for  example,  that  of  immunological  tol-
rance  to  normal  intestinal  microﬂora.11
Within  the  different  PRR  groups,  the  group  made  up  of
oll-like  receptors  (TLR)  has  been  broadly  characterised  as  a
roup  of  crucial  receptors  for  recognition  of  both  PAMP  and
AMP.12 Ten  functional  types  of  TLR  have  been  described
n  human  beings,  which  may  be  located  either  on  a  cellular
embrane  level  or  cytoplasm  level.  On  binding  with  ligands,
he  TLRs  trigger  an  intracellular  signalling  cascade  which
ulminates  in  the  onset  of  an  inﬂammatory  response  through
he  secretion  of  inﬂammatory  and  chemotactic  mediators
nd  the  recruitment  of  immune  cells  to  the  infected  or  dam-
ged  cells.  Although  the  role  of  TLR  in  infectious  processes
as  been  extensively  described,  a  growing  body  of  evidence
uggests  that  these  receptors  could  play  a  key  role  during  the
tart  and  perpetuation  of  low-grade  systemic  inﬂammation
ssociated  with  obesity.13
Unlike  acute  or  classical  inﬂammation  induced  by  PAMP,
he  response  associated  with  different  molecules  derived
c
t
v IL:  interleukin;  LGSI:  low-grade  systemic  inﬂammation;  oxLDL:
rom  a  changed  metabolic  state  or  ‘‘metabolic  DAMP’’  leads
o  a  lower  intensity,  longer-lasting  systemic  inﬂammation.14
ifferent  metabolites  are  linked  as  generators  of  low-
rade  systemic  inﬂammation  through  their  adhesion  to
LRs.14 In  this  way,  both  dyslipidaemia  and  hyperglycaemia
ave  shown  to  decisively  participate  in  the  polarisation  of
acrophages  towards  a  pro-inﬂammatory  phenotype  and
he  concomitant  initiation  of  low-grade  systemic  inﬂamma-
ion  through  activation  of  TLRs.  Speciﬁcally,  it  has  been
nown  for  some  time  that  free  fatty  acids  (FFA),  and
specially  all  the  saturated  ones  such  as  palmitic  acid,
rovoke  a  to  systemic  inﬂammatory  response.12 At  present
e  know  that  this  phenomenon  presents  because  during  dys-
ipidaemia  a  large  quantity  of  FFAs  may  adhere  to  TLR-1,  2
nd  6  located  in  the  surface  area  of  a  macrophage,  form-
ng  heterodimers  which  join  together  with  diacyl  or  triacy
ipopeptides  and  release  inﬂammatory  cytokines.15
Moreover,  apart  from  recognising  lipopolysaccharride
LPS,  a  molecule  derived  from  gram-negative  bacteria),  TLR-
 is  also  able  to  recognise  glycated  serum  proteins,  referred
o  as  advanced  glycation  end  products  (AGE).16 During  a
yperglycemic  state  nonenzymatic  glycosylation  takes  place
n  several  proteins  including  haemoglobin,  albumin  or  low-
ensity  lipoproteins  (LDL)  in  lysine  and  arginine  residues
iving  rise  to  AGEs.  In  cells  such  as  macrophages  these  AGEs
ay  adhere  to  TLR-4,  which  is  over  expressed  in  metabolic
iseases.13 Stimulation  of  TLRs  imitates  a signalling  intra-
ellular  cascades  mediated  by  the  nuclear  factor  kappa  B
NF-B),  which,  once  it  has  translocated  to  the  nucleus,
ctivates  the  transcription  of  genes  encoding  inﬂamma-
ory  cytokines  and  chemokines,  including  IL-1, TNF-
nd  CXCL8,  thereby  initiating  an  inﬂammatory  response  in
esponse  to  the  hyperglycaemia.
Altered  metabolic  states  such  as  dyslipidaemia  and
yperglycaemia  may  therefore  induce  an  inﬂammatory
esponse  in  the  macrophage  through  PRR  activation,  which
ould  later  spread  systemically  when  this  cell  migrates
owards  insulin-dependent  tissue  and  changes  the  microen-
ironment  of  cytokines  in  the  body.  These  studies  thus
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mLow-grade  systemic  inﬂammation  and  the  development  of  m
show  that  one  of  the  possible  therapeutic  strategies  for  the
control  of  low-grade  systemic  inﬂammation  in  the  obese
patient  involves  the  design  of  drugs  which  would  impede
the  adhesion  of  FFA  and  AGE  to  TLR-1,  2,  4  and  6,  or  which
would  block  the  activation  of  cellular  mediators  such  as  NF-
B,  thereby  potentially  inhibiting  the  progress  of  systemic
inﬂammation  and  its  metabolic  consequences.  However,  the
clinical  relevance  of  this  type  of  new  strategy  is  yet  to  be
determined.
Our  review  of  information  up  until  now  has  enabled  us
to  gain  greater  in-depth  awareness  of  cellular  and  molecu-
lar  mechanisms  involved  in  the  establishment  of  low-grade
systemic  inﬂammation  during  obesity.  However,  a  couple
of  interesting  questions  arise  for  the  remainder  of  this
document.  What  are  the  clinical  manifestations  at  the
onset  and  for  the  duration  of  low-grade  systemic  inﬂam-
mation  in  the  obese  patient?  Is  there  any  existing  clinical
evidence  regarding  the  relationship  between  low-grade  sys-
temic  inﬂammation  and  the  development  of  atherogenesis,
diabetes  mellitus  type  2  and  systemic  arterial  hypertension?
Our  response  to  these  questions  is  addressed  below.
Dyslipidaemia,  atherogenesis  and  low-grade
systemic  inﬂammation
There  has  recently  been  a  rise  in  evidence  to  suggest
that  atherogenesis  could  be  the  consequence  of  a  meta-
inﬂammatory  process  with  vascular  involvement,  in  which
the  formation  of  a  plaque  partially  or  totally  obstructs
arterial  light,  leading  to  events  such  as  myocardial  infarc-
tion,  cerebral  vascular  disease  or  sudden  death.17 Both
low-grade  systemic  inﬂammation  and  dyslipidaemia  have
been  identiﬁed  as  decisive  factors  in  atherogenesis  and  the
vascular  risks  involved  therein.17 In  the  nascent  platelet,
oxidised  low  density  lipo  proteins  (oxLDL)  adhere  to  recep-
tors  found  on  the  macrophage  surface,  such  as  CD36,
TLR-4,  the  receptor  for  advanced  glycation  end-products
(RAGE)  and  the  formyl-peptide  receptor  2  (FPR2).18--20 This
interaction  initiates  the  release  of  ROSs,  which  activate
the  nucleotide-binding  oligomerization  domain-like  recep-
tor  family  of  proteins  (NLRP3),  a  complex  of  proteins  with
inﬂammatory  and  apoptotic  activity  in  response  to  PAMP  and
DAMP.21 It  has  also  been  observed  that  the  FFAs  are  able  to
directly  release  inﬂammatory  agents  (TNF- and  IL-1) and
oxidants  (ON)  in  the  endothelial  cell  when  inﬂammasome-
free  mitochondrial  uncoupling  takes  place.22 This  cascade
of  inﬂammatory  events  causes  the  vascular  endothelium  to
release  adhesive  molecules  including  the  intracellular  adhe-
sion  molecule  1  (ICAM-1)  and  the  vascular  cellular  adhesion
molecule  1  (VCAM-1);  these  molecules  drive  the  routing  of
new  macrophages  from  the  periphery  towards  the  endothe-
lium  and  vascular  sub-endothelium.  Due  to  LDL  captation,
invasive  macrophages  of  the  subendothelial  domain  are
transformed  into  foamy  cells,  an  event  which,  together  with
the  migration  of  muscle  cells  with  a  high  ability  to  express
TNF-,  IFN-, IL-1, and  IL-6,  is  key  to  the  thickening  of  the
atherosclerotic  platelet  and  the  increase  of  cardiovascular
risk  in  the  patient.23 Furthermore,  not  only  have  the  oxLDLs
contributed  to  atherosclerosis,  but  numerous  lipids  and  oxi-
dised  phospholipids  have  been  identiﬁed  in  atherosclerotic
platelets,  among  which  the  platelet  activating  factor  is  of
1
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ote  (PAF),  the  oxidised  phospholipids  and  lysophosphatidyl-
holine,  which  are  themselves  alone  capable  of  inducing  the
xpression  of  TNF-, IL-1, IL-6,  TLR-2,  TLR-4  and  NF-B in
acrophages,  and  MCP-1  and  VCAM  in  endothelial  cells.23--25
oreover,  other  molecules,  such  as  pCr  may  be  deposited  in
he  intima  layer  of  the  artery  and  recruitment  of  monocytes-
acrophages  with  inﬂammatory  activity  may  take  place
hrough  low  afﬁnity  receptors  for  peripheral  IgG.26 Several
tudies  also  suggest  that  IL-6  may  play  an  important  role  as  a
ipidaemia  regulator,  since  the  blocking  of  this  inﬂammatory
ediator’s  function  through  the  use  of  tocilizumab  improves
he  relationship  between  total  cholesterol  and  the  high  den-
ity  lipoproteins  (HDL).27 Total  evidence  therefore  suggests
hat  lipid  disruption  is  currently  considered  a  clear  inducer
f  meta-inﬂammation  in  atherogenesis,  because:  (1)  LDLs
nd  oxLDLs  are  clear  inﬂammatory  stimulae,  (2)  atheroscle-
osis  does  not  develop  in  animal  models  or  in  patients  where
ithout  a  signiﬁcantly  high  level  of  these  molecules,  and  (3)
learly  inﬂammatory  multiple  molecules  such  as  pCr  and  IL-6
ay  regulate  the  atherosclerotic  process.27 In  this  apparent
riad  of  dyslipidaemia  --  low-grade  systemic  inﬂammation
- atherogenesis,  one  of  the  topics  of  greatest  interest
or  its  possible  medical  application  is  the  prognostic  value
f  anti-oxLDL  antibodies  in  atherosclerosis,  since  patients
ith  coronary  disease  present  a  reduction  in  anti-oxLDL
nti-bodes  leading  to  greater  severity  of  acute  ischaemic
yndrome.28 Furthermore,  the  infusion  of  anti-oxLDL  anti-
odies  reduces  atherogenesis  in  mice  which  are  susceptible
o  the  development  of  atheroesclerosis.29 However,  a  neu-
ralisation  test  of  these  antibodies  in  prospective  patient
ohorts  needs  to  be  performed  to  determine  their  true  pro-
nostic  value  and  reach  a  more  in-depth  understanding  of
he  role  of  immune  response  in  atherogenesis.
iabetes  mellitus  type  2  and  low-grade  systemic
nﬂammation
iabetes  mellitus  type  2  is  a  disease  of  multifactorial  aeti-
logy  characterised  by  chronic  hyperglycaemia  associated
ith  resistance  to  insulin  activity  and  an  insufﬁcient  com-
ensatory  response  in  the  secretion  of  this  hormone.  A
reat  deal  of  research  studies  indicate  that  the  physiopatho-
enesis  of  this  illness  is  closely  related  with  the  systemic
nﬂammatory  process,  which  could  be  active  prior  to  the
evelopment  of  clinically  detectable  metabolic  changes
Fig.  2).30 Even  the  children  of  people  with  diabetes  mel-
itus  type  2  present  high  inﬂammatory  markers  long  before
hey  present  with  any  metabolic  changes.31
In  diabetes  mellitus  type  2  inﬂammation  of  the  pancre-
tic  islet  plays  an  essential  role.  There  are  two  pathways
ith  regards  to  the  inﬂammatory  process  in  the  pancreatic
:  (1)  activation  of  TLR-2  and  TLR-4  by  metabolic  DAMP  such
s  AGEs,  and  (2)  NLRP3  inﬂammosome  assembly.32 The  result
f  this  process  is  insulitis,  characterised  by  the  continuous
elease  of  IL-6,  IL-8,  TNF- and  MCP-1,  the  activation  of
nsular  macrophages  and  the  recruitment  of  new  peripheral
onocytes-macrophages.  Other  molecules  such  as  IL-12,  IL-
7  and  NADPH  oxidase-1  also  have  a  major  part  to  play  in
slet  inﬂammation.32 In  insulitis,  the  pancreative    cell  is
ost  susceptible  to  the  effects  of  IL-1, since  it  expresses
igher  levels  of  the  receptor  of  this  inﬂammatory  cytokine
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Low-grade systemic inflammation
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Figure  2  Low-grade  systemic  inﬂammation  contributes  to  the  development  of  insulin  resistance  in  several  ways.  AGE:  advanced
glycation end  products;  FFA:  free  fatty  acids;  AKT:  protein  kinase  B;  RNS:  reactive  nitrogen  species;  ROS:  reactive  oxygen  species;
GLUT: glucose  carrier  proteins;  IL:  interleukin;  LGSI:  low-grade  systemic  inﬂammation;  IRS:  insulin  receptor  substrate;  NF-:
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puclear factor  kappa  beta;  oxLDL:  oxidised  low  density  lipo  prote
eceptor; TNF:  tumour  necrosis  factor.
IL-1R1).33 As  predicted  by  our  group  2011,34 blockage  of
he  effects  of  IL-1 with  the  monocolonal  antibody  Gevok-
zumab  led  to  an  improvement  in  the  secretion  of  peptide
,  thereby  lowering  levels  of  glycosylated  haemoglobin  and
nﬂammatory  cytokines  in  patients  with  diabetes  mellitus
ype  2.35
This  inﬂammatory  process  also  simultaneously  affects
ther  tissues  through  a  cascade  of  events  which  currently
onstitute  one  of  the  main  physiopathogenic  theories  in  the
evelopment  of  insulin  resistance  and  diabetes  mellitus  type
.  During  low-grade  systemic  inﬂammation,  the  adipose,
epatic  and  muscular  tissue  are  exposed  to  inﬁltration  of
nﬂammatory  macrophages  which  are  the  producers  of  TNF-
,  a  cytokine  which  directly  interferes  with  the  ability  of
hese  tissues  to  respond  to  insulin.  Under  normal  conditions
i
c
d
r RAGE:  receptor  advanced  glycation  end  products;  TLR:  toll-like
nsulin  adheres  to  a  receptor  located  on  the  surface  of  the
dipocyes,  hepatocytes  and  miocytes,  initiating  an  intra-
ellular  signalling  cascade  mediated  by  the  insulin  receptor
ubstrate  (IRS),  which  activates  AKT  and  ﬁnally  induces  the
obilisation  of  glucose  transporter  proteins  (GLUT-2  and  4)
or  the  incorporation  of  this  glucose  to  the  inside  of  the  cell.
n  the  presence  of  TNF-, activation  of  the  IRS-AKT-GLUT
ignalling  is  inhibited  by  the  action  of  the  responsive  intra-
ellular  pathways  to  TNF-, including  ERK/JNK,  PTP1B  and
F-B,  which  in  turn  directly  compete  with  or  inhibit  phos-
horylation  of  IRS-2,  AKT,  GLUT-2  and  4.36 To  sum  up,  this
nﬂammation  leads  to  a  state  of  hyperglycaemia  and  later  a
ompensatory  state  of  hyperinsulinaemia,  followed  by  clau-
ication  and  apoptosis  of  the  pancreative    cell,  insulitis,
eduction  in  insulin  levels  and  the  establishment  of  diabetes
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mellitus  type  2.  As  previously  mentioned,  hyperglycaemia
per  se  leads  to  a  state  of  systemic  inﬂammation  charac-
terised  by  the  activation  of  macrophages  which  inﬁltrate
the  tissue  and  concomitantly  raise  inﬂammatory  cytokine
levels,  which  perpetuate  low-grade  systemic  inﬂammation
and  its  metabolic  consequences.
Arterial  hypertension  as  a  result  of  multiple
inﬂammatory  mechanisms
As  a  clinical  entity,  systemic  arterial  hypertension  presents
between  20  and  50  years  of  age,  with  a  prevalence  of  up
to  75%  in  advanced  ages.37 Systemic  arterial  hypertension
is  closely  related  to  diseases  such  as:  vascular  disease  of
the  brain,  coronary  disease,  heart  failure,  auricular  ﬁbri-
lation,  and  kidney  failure.  Different  molecular  mechanisms
converge  in  the  development  of  the  systemic  arterial  hyper-
tension  clinical  phenotype  where  the  inﬂammation  appears
to  play  a  central  role  in  the  thickening  of  the  intima  and
media  layers  and  also  arterial  stiffness  in  addition  to  being
highly  important  in  endothelial  dysfunction.
Changes  in  the  expression  proﬁle  of  the  vascular  endothe-
lium  have  been  associated  with  higher  adhesion  and
atherogenicity.  These  changes  include  the  secretion  of
molecules  such  as  soluble  endothelial  selectin,  thrombo-
modulin,  VCAM-1,  ICAM-1  and  the  Von  Willebrand  factor,31,32
and  appear  as  a  consequence  of  the  stimulus  of  several
metabolic  DAMPs  such  as  FFAs,  particularly  unsaturated
fatty  acids.  These  molecules  have  a  negative  effect  on
endothelial  function  on  activating  NF-B and  IL-6  and  facil-
itate  the  production  of  ROS.32 One  of  the  most  prevalent
inﬂammatory  molecules  involved  in  the  development  of  sys-
temic  arterial  hypertension  is  pCr.38 In  a  study  involving  320
non  diabetic  patients  recently  diagnosed  with  hypertension
where  higher  pCr,  soluble  RAGE  (sRAGE)  and  asymmetrical
dimethylarginine  levels  were  observed,  it  was  noted  that
the  highest  sRAGE  rates  correlated  with  a  higher  body  mass
index,  higher  blood  pressure  and  higher  levels  of  pCr.39 The
pCr  levels  reduced  the  production  of  ON  due  to  its  action
on  endothelial  ON  synthase  (eNOS)  and  induced  a  greater
expression  of  type  1  angiotensine  receptors  (ATR1)  in  vas-
cular  smooth  muscle,  facilitating  activation  of  NF-B by
angiotensis  II  and  the  release  of  TNF-, with  negative  impact
on  eNOS.40 It  is  of  note  that  pCr  also  inhibits  prostacyclin
synthase,  which  interferes  with  the  prostacyclin-mediated
vasodilator  effect.41 In  aortic  human  endothelial  cells,  pCr
inhibits  GTP  cyclohydrolase,  lowering  tetrahydrobiopterin
synthesis  (BH4,  co-factor  of  eNOS)  and  stimulating  NADPH
oxidase,  which  increases  ROS  levels.  The  ﬁnal  effect  is
reduction  in  ON  production  and  thereby  in  hypertension.
In  patients  who  lack  morning  blood  pressure  control,  hav-
ing  an  elevated  serum  pCr  level  increases  cardiovascular
risk  by  5.77  times  (IC  95%  2.11--15.81)  in  comparison  with
those  who  have  a  normal  pCr  level.42 The  atheromatous
plaques  in  patients  without  early  morning  blood  pressure
control,  compared  with  those  who  do  not  lack  control,  are
higher  in  inﬂammatory  activity,  characterised  by  a  larger
amount  of  macrophages  and  T  inﬁltrating  lymphocytes,
as  well  as  production  of  NF-B and  TNF-. This  inﬂam-
matory  phenotype  is  associated  with  greater  activity  of
ubiquitin--proteasome,  the  main  non-lysosomal  intracellular
C
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athway  of  protein  degradation  marked  for  degradation  by
roteasome  activity.43 This  pathway  is  necessary  for  NF-B
ctivation  as  it  degrades  the  NF-B kinase  inhibiting  proteins
IKK).  In  hypertensive  animal  models  it  has  been  determined
hat  the  inﬁltration  of  tissues  by  macrophages  and  NF-B  and
L-1  production  is  more  intense  in  the  kidney,  which  stimu-
ates  renin--angiotensin--aldosterone  system  activation  and
lays  a  part  in  kidney  injury  induced  by  hypertension.44
Recognition  of  systemic  arterial  hypertension  as  a  sys-
emic  inﬂammatory  process  is  fundamental  not  only  for
nderstanding  the  genesis  of  the  disease  but  also  the  devel-
pment  of  any  complications  associated  with  it.  From  an
mmunological  viewpoint  treatment  approach  could  there-
ore  have  patient  beneﬁts.  For  example,  in  patients  with
eart  failure  secondary  to  systemic  arterial  hypertension,
he  beneﬁcial  effects  of  carvedilol  are  lower  in  those  who
ave  higher  levels  of  inﬂammatory  cytokines  such  as  TNF-
 and  IL-18.45 To  sum  up,  low-grade  systemic  inﬂammation
ot  only  plays  a  part  in  the  development  of  systemic  arte-
ial  hypertension  but  is  also  associated  with  its  severity  and
ontributes  to  the  development  of  complications  such  as
ypertrophy  and  left  ventricular  dysfunction,  arrhythmoge-
esis  and  atherosclerosis.  Research  is  therefore  essential
or  reaching  a better  understanding  of  the  disease  and  an
ptimum  approach  for  patient  care.
onclusions
he  evidence  presented  suggests  that  low-grade  systemic
nﬂammation  plays  an  essential  role  in  the  development  of
etabolic  diseases,  such  as  dyslipidaemia,  atherogenesis,
iabetes  mellitus  type  2  and  systemic  arterial  hypertension.
his  meta-inﬂammation  causes  activation  of  intracellu-
ar  signals  leading  to  the  releases  of  local  and  systemic
nﬂammatory  factors,  which  feedback  and  interconnect
ro-inﬂammatory  producers  of  inﬂammatory  cytokines  and
OS  macrophages  to  adipose,  muscular  and  liver  tissues.
nce  established,  the  low-grade  systemic  inﬂammation
romotes  and  perpetuates  metabolic  changes  establish-
ng  a  vicious  circle  leading  to  pathological  processes
uch  as  insulin  resistance,  atherosclerosis  and  endothe-
ial  dysfunction.  Breaking  the  cycle  therefore  depends  on
imultaneously  controlling  both  metabolic  and  inﬂamma-
ory  components.  Future  research  must  therefore  aim  at
esigning  anti-inﬂammatory  therapies  leading  to  appro-
riate  metabolic  regulation,  whilst  taking  into  account
ytokine  and  circulating  immune  cell  levels,  factors  of  tran-
cription  and  adhesion,  and  the  patient’s  metabolic  DAMP
roﬁle.  This  more  integrated  approach,  together  with  clin-
cal  data,  could  contribute  to  the  identiﬁcation  of  different
eta-inﬂammation  phenotypes  depending  on  the  level  and
elationship  between  their  components,  which,  in  turn,
ould  be  clinically  identiﬁed  by  biomarkers  for  predicting
 patient’s  evolution  with  a  metabolic  disease  and  establish
ustomised  anti-inﬂammatory  therapies  based  on  molecular
vidence.onﬂict of interests
he  authors  have  no  conﬂict  of  interests  to  declare.
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